^
Association details:
Biomarker:No biomarker
Cancer:Follicular Lymphoma
Drug:Ruxience (rituximab-pvvr) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
04/01/2020
Excerpt:
Ruxience is indicated for the treatment of previously untreated patients with stage III‑IV follicular lymphoma in combination with chemotherapy.
Secondary therapy:
Chemotherapy